These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10087434)

  • 1. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program.
    Arkin S; Cooper HA; Hutter JJ; Miller S; Schmidt ML; Seibel NL; Shapiro A; Warrier I
    Haemostasis; 1998; 28(2):93-8. PubMed ID: 10087434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
    Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
    Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
    Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
    Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
    Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
    Nakar C; Cooper DL; DiMichele D
    Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
    Hedner U; Brun NC
    Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
    Kavakli K; Demartis F; Karimi M; Eshghi P; Neme D; Chambost H; Sommer L; Zak M; Benson G
    Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
    Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
    Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
    Tiede A; Friedrich U; Stenmo C; Allen G; Giangrande P; Goudemand J; Hay C; Holmström M; Klamroth R; Lethagen S; McKenzie S; Miesbach W; Negrier C; Yuste VJ; Berntorp E
    J Thromb Haemost; 2011 Jun; 9(6):1191-9. PubMed ID: 21489128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Young G; Cooper DL; Gut RZ;
    Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.